Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 98-patient European Phase III trial of Fosrenol lanthanum carbonate, there were no
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury